Medication details to pay attention to in the latest instructions for bortezomib

The route of administration and dosage schedule are matters that require special attention in the instructions. Bortezomib can be administered intravenously or subcutaneously, but in recent years guidelines have tended to recommend subcutaneous injection to reduce the risk of peripheral neuropathy. The standard dose is 1.3 mg/m², usually administered 2 times a week, followed by a one-week break to form a treatment cycle. The instructions remind doctors to adjust the dosing interval or dosage according to the patient's specific conditions (such as age, weight, liver and kidney function, etc.), especially in combination treatment regimens.

Nervous system toxicity monitoring is the focus of drug management. One of the common adverse reactions of bortezomib is peripheral neuropathy, including paresthesia, numbness, tingling, etc. In severe cases, it can affect the quality of life and even require discontinuation of the drug. The latest instructions recommend that the level of neurotoxicity be assessed before each medication. Once grade 2 or above neuropathy occurs, dosage adjustment or dosing interval should be considered, and the medication should be discontinued if necessary.

The management of patients with hepatic and renal insufficiency is also clearly outlined. The instructions indicate that patients with mild to moderate hepatic impairment need to reduce the starting dose of bortezomib, while patients with severe hepatic impairment should use it with caution or under close monitoring. In addition, although renal insufficiency has little effect on its clearance, patients with end-stage renal disease still need to be given bortezomib after dialysis to ensure stable drug efficacy.

Drug interactions and infection risk control are also medication details that cannot be ignored in the instructions. Bortezomib may interact with drugs related to CYP3A4 metabolizing enzymes. In particular, combination with strong inhibitors or inducers should be avoided. At the same time, as an immune function suppressant, bortezomib can increase the risk of infection, so the instructions recommend that patients should be evaluated for potential infection before use. Some high-risk patients also need to use antiviral drugs prophylactically, such as acyclovir to prevent the occurrence of herpes zoster.

Reference materials:https://www.drugs.com/donanemab.html